Surgery – Means for introducing or removing material from body for... – Treating material introduced into or removed from body...
Reexamination Certificate
2011-04-26
2011-04-26
Bockelman, Mark W (Department: 3766)
Surgery
Means for introducing or removing material from body for...
Treating material introduced into or removed from body...
C604S522000, C604S021000
Reexamination Certificate
active
07931640
ABSTRACT:
A method is disclosed for delivering molecules such as pharmaceutical drugs and nucleic acids into skeletal muscle in vivo. The molecule is first injected into the muscle at one or multiple sites. Immediately or shortly after injection, electrodes are placed flanking the injection site and a specific amount of electrical current is passed through the muscle. The electrical current makes the muscle permeable, thus allowing the molecule to enter the cell. In the case where nucleic acid is injected, the efficiency of transfer permits expression of protein encoded by the nucleic acid in an amount that exhibits systemic biological activity and which generates a robust immune response.
REFERENCES:
patent: 4596556 (1986-06-01), Morrow et al.
patent: 4702732 (1987-10-01), Powers et al.
patent: 4913699 (1990-04-01), Parsons
patent: 5273525 (1993-12-01), Hofmann
patent: 5304120 (1994-04-01), Crandell et al.
patent: 5318514 (1994-06-01), Hofmann
patent: 5389069 (1995-02-01), Weaver
patent: 5468223 (1995-11-01), Mir
patent: 5501662 (1996-03-01), Hofmann
patent: 5674267 (1997-10-01), Mir et al.
patent: 5702359 (1997-12-01), Hofmann et al.
patent: 5730723 (1998-03-01), Castellano et al.
patent: 5736524 (1998-04-01), Content et al.
patent: 5810762 (1998-09-01), Hofmann
patent: 5944710 (1999-08-01), Dev et al.
patent: 5964726 (1999-10-01), Korenstein et al.
patent: 5993434 (1999-11-01), Dev et al.
patent: 6009347 (1999-12-01), Hofmann
patent: 6041252 (2000-03-01), Walker et al.
patent: 6110161 (2000-08-01), Mathiesen et al.
patent: 6261281 (2001-07-01), Mathiesen et al.
patent: 6440944 (2002-08-01), Bruder et al.
patent: 6610044 (2003-08-01), Mathiesen
patent: 6958060 (2005-10-01), Mathiesen et al.
patent: 2002/0168339 (2002-11-01), Piechaczyk et al.
patent: 2003/0018006 (2003-01-01), Tao et al.
patent: 2006/0041219 (2006-02-01), Mathiesen et al.
patent: 0235113 (1987-09-01), None
patent: 61-000361 (1986-01-01), None
patent: WO 89/06555 (1989-07-01), None
patent: WO 94/22526 (1994-10-01), None
patent: WO 95/19805 (1995-07-01), None
patent: WO 95/23211 (1995-08-01), None
patent: WO 96/32155 (1996-10-01), None
patent: WO 97/07826 (1997-03-01), None
patent: WO 98/27966 (1998-07-01), None
patent: WO 98/31808 (1998-07-01), None
patent: WO 98/43702 (1998-10-01), None
patent: WO 99/01157 (1999-01-01), None
patent: WO 99/01175 (1999-01-01), None
patent: WO 00/45823 (2000-08-01), None
Aase et al, “The use of a hapten-Fab conjugate to sensitize target cells for antibody-dependent complement-mediated lysis and antibody-dependent cell-mediated cytotoxicity,”J. Immunol. Methods136(2):185-191 (1991).
Abe et al, “Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy,”Gene Ther. 3(11):988-993 (1996).
Acsadi et al, “Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs,”Nature352(6338):815-818 (1991).
Aihara et al, “Gene transfer into muscle by electroporation in vivo,”Nat. Biotechnol. 16(9):867-870 (1998).
Arafat et al, “Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv,”Gene Ther. 9(4):256-262 (2002).
Bachy et al, “Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse,”Vaccine19(13-14):1688-1693 (2001).
Bhatt et al, “Rhabdomyolysis due to pulsed electric fields,”Plast. Reconstr. Surg. 86(1):1-11 (1990).
Biragyn et al, “B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions,”lmmunol. Rev. 170(1):115-126 (1999).
Block et al, “Nonthermally mediated muscle injury and necrosis in electrical trauma,”J. Burn Care&Rehabil. 16(6):581-588 (1995).
Bo et al, “Elementary Study of β—Galactosidase Nucleic Acid Immunization,”Chinese J. of lmmunol. 13(3):146 (1997) (abstract).
Bogen et al, “Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules,”Eur. J. Immunol. 16(11):1373-1378 (1986).
Bogen et al, “Processing and Presentation of Idiotypes to MHC-Restricted T Cells,”Int. Rev. lmmunol. 10(4):337-355 (1993).
Chang et al, “A Single Intramuscular Injection of Recombinant Plasmid DNA Induces Protective Immunity and Prevents Japanese Encephalitis in Mice,”J. Virol. 74(9):4244-4252 (2000).
Chang et al, “Intramuscular Administration of Expression Plasmids Encoding Interferon-γ Receptor/IgG1or IL-4/IgG1Chimeric Proteins Protects from Autoimmunity,”J. Gene Med. 1(6):415-423 (1999).
Cohen et al, “Agrin-Induced Postsynaptic-like Apparatus in Skeletal Muscle Fibers in Vivo,”Mol. Cell. Neurosci. 9(4):237-253 (1997).
Collas et al, “The Nuclear Localization Sequence of the SV40 T Antigen Promotes Transgene Uptake and Expression in Zebrafish Embryo Nuclei,”Transgenic Res. 5(6):451-458 (1996).
Colombat et al, “Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation,”Blood97(1):101-106 (2001).
Danko et al, “Pharmacological enhancement of in vivo foreign gene expression in muscle,”Gene Ther. 1(2):114-121 (1994).
Davis et al, “Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression,”Hum. Gene Ther. 4(2):151-159 (1993).
Denis et al, “Vaccination with Plasmid DNA Encoding Mycobacterial Antigen 85A Stimulates a CD4+and CD8+T-Cell Epitopic Repertoire Broader than That Stimulated by Mycobacterium tuberculosis H37Rv Infection,”Infect. Immun. 66(4):1527-1533 (1998).
Di Marco et al, “Identification of ciliary neurotrophic factor (CNTF) residues essential for leukemia inhibitory factor receptor binding and generation of CNTF receptor antagonists,”Proc. Natl. Acad. Sci. USA93(17):9247-9252 (1996).
Donoghue et al, “Rostrocaudal gradient of transgene expression in adult skeletal muscle,”Proc. Natl. Acad. Sci. USA88(13):5847-5851 (1991).
Eidem et al, “Recombinant antibodies as carrier proteins for sub-unit vaccines: influence of mode of fusion on protein production and T-cell activation,”J. Immunol. Methods245(1-2):119-131 (2000).
Feldmann et al, “Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies,”Joint Bone Spine69(1):12-18 (2002).
Forconi et al, “Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses,”Immunology107(1):39-45 (2002).
Heller et al, “In vivo gene electroinjection and expression in rat liver,”FEBS Letter389(3):225-228 (1996).
Hoch et al, “Structural domains of agrin required for clustering of nicotinic acetylcholine receptors,”EMBO J. 13(12):2814-2821 (1994).
Hofmann et al, “Electrochemotherapy: Transition from Laboratory to the Clinic,”IEEE Engineering in Medicine and Biology15(6):124-132 (1996).
Huston et al, “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli,” Proc. Natl. Acad. Sci. USA 85(16):5879-5883 (1988).
Kadowaki et al, “Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation,”Vaccine18(25):2779-2788 (2000).
Katsumi et al, “Humoral and cellular immunity to an encoded protein induced by direct DNA injection,”Hum. Gene Ther. 5(11):1335-1339 (1994).
King et al, “DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity again
Lomo Terje
Mathiesen Iacob
Bockelman Mark W
Inovio AS
Kim Thomas
LandOfFree
Method for muscle delivery of drugs, nucleic acids and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for muscle delivery of drugs, nucleic acids and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for muscle delivery of drugs, nucleic acids and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2717423